The Latest

New Campaign, Toolkit Gets Providers PrEP'd for Women

New York City aims to expand PrEP and PEP access by educating more clinicians that serve women.

By Kenyon Farrow

This Week in HIV Research: Fentanyl Smooths the Path for HIV

April 4, 2019: what’s driving the HIV outbreak in northeastern Massachusetts; race-gender HIV disparities among Baltimore sex workers; high PrEP interest, low awareness among southern black women; naltrexone implants for opioid dependence.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Prevention and Treatment in the Real World

Impact of intimate partner violence on PrEP attitudes among women; evolution of first-line HIV treatment failure rates; cumulative low-level viremia and virologic failure risk; HIV drug levels in breast milk versus plasma.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: A Long-Acting Popularity Contest

The most popular form of long-acting HIV treatment; telehealth for PrEP uptake among young MSM of color; PrEP awareness and usage among Rhode Island women; assessing cognitive benefits of switching off of efavirenz.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Transgender Women in the Spotlight

Black transgender women and the HIV care continuum; PrEP uptake potential among trans women; an update on U.S. mother-to-child HIV transmission; is extra measles vaccination necessary?

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: The PrEP Sex/Race Gap

PrEP access appears far from equal in the U.S.; HIV treatment and viral suppression disparities in Europe; how today’s hepatitis C treatments affect mortality; sex-based differences in cognitive impairment.

By Barbara Jungwirth and Myles Helfand

This Week in HIV Research: Gender Disparities Among the Formerly Incarcerated

Post-incarceration HIV outcomes worse among women; no drug resistance despite apparent PrEP failure; cost-efficacy of adherence self-management; additional cancers in HIV-positive cancer survivors.

By Barbara Jungwirth and Myles Helfand

Making Clinical Trials of PrEP More Inclusive of Women, No Matter Their Pregnancy Status

Three new trials of HIV prevention drugs seek to answer directly a question that researchers inside and outside the field of HIV have explicitly avoided for years: How do drugs work -- and are they safe -- in pregnant and breastfeeding women?

By Heather Boerner

On-Demand PrEP Is Great. Now, What About Women?

What do on-demand PrEP advances seen in men mean for a developing a biomedical prevention agenda for women?

By Danielle M. Campbell, M.P.H.

What Are the Factors That Make Women in the U.S. South Eligible for PrEP?

What needs to be done to ensure that the women most vulnerable to HIV are being identified and made more knowledgeable about PrEP? And what are the demographic, sociobehavioral and clinical factors that made women the most likely candidates for PrEP?

By Kellee Terrell